Who Supplies Vaccine to India from MEXICO

Importing finished pharmaceutical formulations containing vaccines into India requires compliance with the Drug and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945. The Central Drugs Standard Control Organisation (CDSCO) oversees the registration and import of such products. An Importer License issued by the Directorate General of Foreign Trade (DGFT) is mandatory. The vaccine formulations must be registered with CDSCO, which involves submitting Form 40 or 41, depending on the product type. The registration process includes providing a Certificate of Pharmaceutical Product (CoPP), stability data (preferably ICH Zone IV), and a Free Sale Certificate from the country of origin. The timeline for import drug registration can vary but typically ranges from 6 to 12 months. For vaccines under HS Code 30024200, specific requirements include demonstrating the product's safety and efficacy, along with compliance with the Indian Pharmacopoeia standards.

Imported vaccine formulations are subject to quality testing by CDSCO-approved laboratories. Each batch must undergo testing to ensure compliance with Indian standards. A Certificate of Analysis (CoA) from the manufacturer is required, detailing the product's composition, manufacturing process, and quality control measures. Stability data, preferably in ICH Zone IV conditions, must be provided to demonstrate the product's shelf-life under Indian climatic conditions. The Indian Pharmacopoeia sets the standards for quality, purity, and strength. Upon arrival, customs drug inspectors conduct port inspections to verify compliance with regulatory requirements. If a batch fails to meet the required standards, it may be rejected, re-exported, or destroyed, depending on the severity of the non-compliance.

Between 2024 and 2026, the CDSCO has implemented several regulatory updates affecting the import of finished vaccine formulations. The Production Linked Incentive (PLI) scheme introduced in 2024 aims to boost domestic manufacturing and may impact the volume of finished formulation imports. Bilateral agreements between India and Mexico have facilitated smoother trade relations, including mutual recognition of Good Manufacturing Practices (GMP), which can expedite the import process. These developments are expected to influence the dynamics of finished vaccine formulation imports from Mexico to India.

India imports finished vaccine formulations to meet the demand for patented or branded products, specialized dosage forms, and vaccines not produced domestically. The domestic pharmaceutical industry may lack the capacity or technology to manufacture certain vaccines, necessitating imports. The market size for vaccine imports in India is substantial, with a growing need for diverse and specialized vaccines to address public health requirements.

The Basic Customs Duty (BCD) for vaccines under HS Code 30024200 is 10%. The Social Welfare Surcharge (SWS) is 10% of the BCD. The Integrated Goods and Services Tax (IGST) is levied at 5%. There are no exemptions or preferential duty rates for imports from Mexico. The total landed duty percentage is calculated by summing the BCD, SWS, and IGST, resulting in a total duty of 25%.

India sources finished vaccine formulations from Mexico due to the availability of patented formulations, specialized dosage forms, and high-quality products. Mexico's pharmaceutical industry is recognized for its adherence to international quality standards and regulatory compliance. While other suppliers like China, Germany, and the United States also export vaccines to India, Mexico's competitive advantage lies in its unique product offerings and established trade relations with India. Mexico's share in India's vaccine import market is significant, reflecting its strong position as a supplier.

India imports finished vaccine formulations from Mexico due to the availability of patented formulations, specialized dosage forms, and high-quality products that may not be produced domestically. Mexico's pharmaceutical industry adheres to international quality standards and regulatory compliance, making it a reliable source for vaccines. Specific formulations supplied by Mexico that India does not manufacture include certain veterinary vaccines and specialized human vaccines.

Compared to other origins like China, the European Union, and the United States, Mexico offers competitive pricing, high-quality products, and compliance with international standards. While China may offer lower prices, concerns about quality and regulatory compliance can be a drawback. The European Union and the United States provide high-quality products but at higher prices. Mexico's unique advantage lies in its balance of quality, cost, and regulatory compliance, making it an attractive source for India.

Potential risks for Indian importers include single-source dependency, currency fluctuations, regulatory changes, quality incidents, and shipping disruptions. Past shortages have been minimal, but importers should maintain contingency plans to mitigate these risks.

1. 1Dual-Sourcing: Engage multiple suppliers to reduce dependency on a single source.
2. 2Inventory Planning: Maintain adequate stock levels to buffer against supply chain disruptions.
3. 3Payment Terms: Negotiate favorable terms such as Letters of Credit (LC), Documents Against Acceptance (DA), or Documents Against Payment (DP).
4. 4Minimum Order Quantities (MOQs): Clarify MOQs with suppliers to optimize procurement costs.
5. 5Supplier Qualification: Conduct thorough due diligence to ensure supplier reliability and product quality.

1. Obtain a valid Importer